Protara Therapeutics Inc
protaratx.comWhat Do They Do?
Develops an investigational cell therapy for bladder cancer and lymphatic malformations, plus intravenous choline chloride for people receiving nutrition and fluids through a vein.
10-K for FY2025, filed Mar 10, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$21.7MView ↗
- ▲ +45% (Loss)
- vs −$15M in Q2 FY2025
Broader choline treatment goal
The program's aim widened from treating liver disease associated with intestinal failure to providing choline to people receiving nutrition and fluids through a vein when oral or tube feeding is not an option.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 10, 2026The third development program in our portfolio is intravenous, or IV, Choline Chloride, an investigational phospholipid substrate…View ↗
Who Do They Compete With?
Competes with Merck &, Endo International, Ferring, ImmunityBio, Janssen, Japanese BCG Laboratory, Pfizer, CG Oncology, enGene, Urogen Pharma, Theralase Technologies, Auro BioSciences, Verity, AstraZeneca, Bristol-Myers Squibb, Roche Group, Asieris Pharmaceuticals, BeiGene, NanOlogy, and Linton Pharm
10-K for FY2025, filed Mar 10, 2026TARA-002, if approved for the treatment of NMIBC, would be subject to competition from existing treatment methods of surgery, chemotherapy…View ↗
Loading...
